The U.S. Food and Drug Administration (FDA) has reviewed Inhibikase Therapeutics’ (NASDAQ: IKT) Investigational New Drug (IND) application and issued a Study May Procced (SMP) letter for its drug candidate IkT-001Pro in the treatment of Chronic Myelogenous Leukemia (CML).
Vinco Ventures Inc (NASDAQ:BBIG) has appointed Ross Miller as co-Chief Executive Officer along with John Colucci and Lisa King, effective immediately.…
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced that its lead asset BCX9930 has demonstrated >99 percent suppression of the alternative pathway (AP), and that >98 percent suppression was maintained for 24 hours post-dosing, in patients with C3 glomerulopathy (C3G), a rare renal disease that is characterized by dysregulation of the AP of the complement system.
89bio Inc (NASDAQ:ETNB) announced the presentation of data from the ENTRIGUE Phase 2 proof-of-concept trial of pegozafermin in severe hypertriglyceridemia (SHTG)…
This recommendation may help reduce the risk of the flu and flu-related complications in this high-risk population
Fluzone® High-Dose Quadrivalent (Influenza Vaccine) and
Cathie Wood-led Ark Investment Management loaded up on 50,263 shares of Teladoc Health Inc (NYSE: TDOC), via the firm’s ARK Genomic Revolution ETF (NYSE: ARKG), valued at over $1.7 mi